PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the Subcommittee on Health.
Congressional Research Service
Version 00 · Introduced in House · May 19, 2015
Delivering Antimicrobial Transparency in Animals Act of 2015
This bill amends the Federal Food, Drug, and Cosmetic Act to revise reporting requirements for new animal drugs containing an antimicrobial.
Certain live poultry dealers, swine contractors, and feed lot operators who purchase, contract, or manufacture animal feed containing a new antimicrobial animal drug must annually report to the Food and Drug Administration, by food-producing animal, the amount of drug per kilogram of feed, and the quantity of feed sold or distributed. Additional information must be provided for feed sold or distributed under a veterinary feed directive.
Showing the opening paragraphs of the official summary.
The FDA may specify alternative reporting requirements to improve the accuracy of reports, lessen the burden of reporting, facilitate providing public summaries of reports, or improve the FDA's ability to use reports or the public's ability to use summaries.
The FDA must publish summaries of these reports and reports from sponsors of new antimicrobial animal drugs, with data reported by antimicrobial drug class. Alternative reporting requirements are specified for antimicrobial drug classes with fewer than three new animal drugs.
The FDA must increase collaboration and coordination with the Department of Agriculture to expand the collection of data on the use of antimicrobials on food-producing animals and to provide information for the Animal and Plant Health Inspection Service and Economic Research Service.
The Government Accountability Office must evaluate the voluntary approach used by the FDA to eliminate injudicious use of antimicrobial drugs in food-producing animals and the effectiveness of FDA data collection activities regarding antimicrobial resistance.
People & committees
Rep. Slaughter, Louise McIntosh [D-NY-25] · D–NY
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We currently store references to these documents.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Aug 12, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.2459 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.2459 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.2459 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.2459 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.